Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › proliferative diabetic retinopathy

Proliferative diabetic retinopathy

Part of Diabetes

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for proliferative diabetic retinopathy

13 trials tracked for proliferative diabetic retinopathy: 7 in phase 3 or 4 and 3 with published results. The most-cited published study has 765 citations.

13Trials tracked
7Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 2 Phase 3 5 Phase 2 4 Phase 1 1 Other / NA 1
  1. Phase 3 Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy Completed · 765 cited
  2. Phase 3 Anti-VEGF vs. Prompt Vitrectomy for VH From PDR Completed · 138 cited
  3. Phase 3 Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy Completed
  4. Phase 4 Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy Completed
  5. Phase 4 Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy Completed
  6. Phase 3 Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N) Completed
Show 7 more trials
  1. Phase 3 Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy Completed
  2. Phase 2 Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema Completed
  3. Phase 2 Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging Completed
  4. Phase 2 Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy Completed
  5. Phase 2 Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy Completed
  6. Phase 1 Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery Completed
  7. N/A Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy Completed

Showing the 13 most-cited and recently-updated of 13 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Proliferative diabetic retinopathy: what the trials found

Several anti-VEGF agents have been evaluated for the management of proliferative diabetic retinopathy (PDR). Brolucizumab 6 mg demonstrated significant efficacy in maintaining vision and reducing PDR, with a statistically significant number of subjects showing no PDR at week 54 (p<0.001) and week 96 5. Ranibizumab has shown varying results across studies; while one trial showed a significant reduction in central subfield thickness via OCT (p<0.01) 7, another reported significant improvements in the ability to complete panretinal photocoagulation (PRP) without vitrectomy (p=0.05) 6.

Bevacizumab was associated with significantly lower rates of reoperation (p=0.033), intraoperative hemorrhage (p=0.025), and postoperative vitreous hemorrhage (p=0.006) in specific clinical contexts 2. Additionally, bevacizumab showed significant results regarding recurrent vitreous hemorrhage incidence (p<0.05) 13. Other anti-VEGF agents include Conbercept 1, 0.5-mg Ranibizumab 3, and 2-mg Aflibercept 4, the latter of which was evaluated using ETDRS visual acuity letter scores and Snellen equivalent ranges.

Ranibizumab has also been shown to impact neovascularization area (measured in pixels) and macular edema thickness, with some patients achieving a gain of 3 or more lines of vision on ETDRS charts 11. Safety profiles for ranibizumab included specific observations regarding drug-related ocular and systemic risks (p=0.01) 6.

Recent results — preliminary, needs further review

  • Aflibercept showed consistent rates of neovascularization regression across multiple groups, with 0% of subjects showing increased neovascularization 9.
  • Emixustat hydrochloride is currently under investigation in Phase 2 trials 8.
  • Dexamethasone intravitreal implant is being evaluated in Phase 2 studies 10.

For the clinician treating this condition

  • Brolucizumab shows significant efficacy in reducing PDR and maintaining BCVA at 54 and 96 weeks 5.
  • Bevacizumab is associated with statistically significant reductions in reoperation, intraoperative hemorrhage, and postoperative vitreous hemorrhage compared to other metrics [2, 13].
  • Ranibizumab has demonstrated significant impact on central subfield thickness and the feasibility of completing PRP without vitrectomy [6, 7].
  • Anti-VEGF agents like Aflibercept and Ranibizumab show varied but measurable impacts on neovascularization regression and macular edema [9, 11].

AI synthesis of 12 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Perioperative anti-VEGF injections improve vision and reduce bleeding in proliferative diabetic retinopathy
Ophthalmology Meta-analysis
Perioperative anti-VEGF injections improve vision and reduce bleeding in proliferative diabetic retinopathy Anti-VEGF injections before eye surgery improve vision and reduce bleeding in diabetic retinopathy
This network meta-analysis evaluated the timing of perioperative anti-VEGF injections for proliferative diabetic retinopathy. Results indica…
A network meta-analysis of 2,646 eyes found that perioperative anti-VEGF injections improved vision and reduced bleeding in patients with pr…
Jun 1, 2026
Ranibizumab plus PRP reduces residual disc neovascularization versus monotherapy in proliferative diabetic retinopathy
Rheumatology Cohort
Ranibizumab plus PRP reduces residual disc neovascularization versus monotherapy in proliferative diabetic retinopathy Adding Laser to Eye Injections Cuts Treatment Burden for Diabetic Eye Disease
This retrospective cohort study included 238 patients with proliferative diabetic retinopathy.
Combining injections with laser treatment for diabetic eye disease significantly reduces future procedures and complications while preservin…
Frontiers Apr 28, 2026

Research across Diabetes

Related studies from across the Diabetes family.

AI-OCT reports reduced false-positive DME referral rates from 69.1% to 24.1%
Diabetes & Endocrinology RCT
AI-OCT reports reduced false-positive DME referral rates from 69.1% to 24.1% AI technology reduces unnecessary referrals for diabetic macular edema
This randomized clinical trial evaluated the impact of AI-OCT reports on identifying diabetic macular edema (DME) in patients with diabetes.…
New research shows that adding AI-powered imaging can significantly cut down on false alarms when screening patients for eye issues caused b…
JAMA Jul 21, 2026
Vitamin D supplementation shows low certainty reductions in urinary markers for diabetic kidney disease
Nephrology Meta-analysis
Vitamin D supplementation shows low certainty reductions in urinary markers for diabetic kidney disease Vitamin D shows limited benefit for diabetic kidney disease
This umbrella review meta-analysis evaluates vitamin D and its analogs in patients with diabetic kidney disease. While some reduction in uri…
Vitamin D may lower protein in urine for diabetic kidney disease, but evidence is weak and no benefit for kidney function or survival.
Frontiers Jul 19, 2026
Balanced crystalloids reduce time to DKA resolution by 1.60 hours compared to 0.9% saline
Pediatrics Meta-analysis
Balanced crystalloids reduce time to DKA resolution by 1.60 hours compared to 0.9% saline Balanced Crystalloids May Speed Recovery in Pediatric Diabetic Ketoacidosis
This meta-analysis of 320 pediatric patients with diabetic ketoacidosis found that balanced crystalloids significantly reduced the time to D…
A review of data suggests balanced crystalloid fluids may resolve diabetic ketoacidosis faster than standard saline in children.
Frontiers Jul 17, 2026
Early subcutaneous basal insulin plus IV insulin reduces time to DKA resolution by 4.06 hours
Diabetes & Endocrinology Meta-analysis
Early subcutaneous basal insulin plus IV insulin reduces time to DKA resolution by 4.06 hours Early Subcutaneous Insulin Shortens Recovery Time for Diabetic Ketoacidosis
This meta-analysis of randomized controlled trials evaluated adding early subcutaneous basal insulin to intravenous insulin for adults with …
Adding early subcutaneous insulin to IV treatment can speed up recovery for patients with diabetic ketoacidosis without increasing safety ri…
Jul 7, 2026
Fluocinolone Acetonide Implant Shows Reduced Injection Frequency for Diabetic Macular Edema
Ophthalmology RCT
Fluocinolone Acetonide Implant Shows Reduced Injection Frequency for Diabetic Macular Edema Fluocinolone Acetonide Implant May Reduce Injection Frequency for DME
A Phase 4 trial shows fluocinolone acetonide implants achieve similar visual outcomes to aflibercept with significantly fewer total injectio…
A new eye implant for diabetic macular edema may significantly reduce the number of monthly injections needed to maintain vision.
Jul 5, 2026
miR-29a-3p and miR-204-5p are downregulated in diabetic nephropathy as potential biomarker candidates
Ophthalmology Meta-analysis
miR-29a-3p and miR-204-5p are downregulated in diabetic nephropathy as potential biomarker candidates Specific MicroRNA Signatures Linked to Type 1 Diabetes Complications
This systematic review and meta-analysis of 9 studies involving 34 contrasts identified specific circulating miRNA signatures associated wit…
Researchers identified specific microRNA signals that may help track kidney and eye damage in patients with Type 1 Diabetes.
Jul 5, 2026
High prevalence of microvascular and macrovascular complications among adult Ugandans with diabetes
Diabetes & Endocrinology Meta-analysis
High prevalence of microvascular and macrovascular complications among adult Ugandans with diabetes High rates of diabetes complications found in adult Ugandans
This meta-analysis examined the prevalence of various diabetic complications, including neuropathy and retinopathy, in a large cohort of adu…
More than half of Ugandan adults with diabetes suffer from nerve damage, highlighting a critical need for earlier screening and better care.
Jun 12, 2026
Immunometabolic dysregulation drives hyperalgesia and hypoesthesia in diabetic peripheral neuropathy
Neurology Sys. Review
Immunometabolic dysregulation drives hyperalgesia and hypoesthesia in diabetic peripheral neuropathy New research explores how inflammation drives nerve damage in diabetes
This narrative review explores the pathophysiology of diabetic peripheral neuropathy, focusing on how hyperglycemia, lipotoxicity, and intes…
Chronic high blood sugar causes more than just high glucose; it triggers a cycle of inflammation and immune stress that damages nerves.
Frontiers Jun 12, 2026
Chronic hyperglycemia causes multi-level nerve damage across the peripheral, autonomic, and central nervous systems
Diabetes & Endocrinology Sys. Review
Chronic hyperglycemia causes multi-level nerve damage across the peripheral, autonomic, and central nervous systems Understanding how high blood sugar damages the entire nervous system in diabetes
This narrative review synthesizes how chronic hyperglycemia impacts the entire neuroaxis in patients with diabetes. It details metabolic and…
High blood sugar can damage nerves throughout the whole body. This affects your senses, movement, and internal organs.
Frontiers Jun 10, 2026
Intravitreal ziv-aflibercept reduces central macular thickness and improves visual acuity in DME and RVO
Ophthalmology Meta-analysis
Intravitreal ziv-aflibercept reduces central macular thickness and improves visual acuity in DME and RVO Trial shows ziv-aflibercept improves vision in macular edema cases
This systematic review and meta-analysis of 5 RCTs and 8 observational studies found that intravitreal ziv-aflibercept significantly reduced…
A new eye treatment called ziv-aflibercept may help reduce swelling and improve vision for patients with specific types of macular edema.
Jun 7, 2026
Local antibiotic delivery systems increase healing rates in diabetic foot osteomyelitis compared with control groups in this meta-analysis
Infectious Disease Meta-analysis
Local antibiotic delivery systems increase healing rates in diabetic foot osteomyelitis compared with control groups in this meta-analysis Local Antibiotics May Boost Healing in Diabetic Foot Infections
This systematic review and meta-analysis evaluated local antibiotic delivery systems versus control groups for patients with diabetic foot o…
A new analysis suggests local antibiotic delivery may improve healing for diabetic foot bone infections, but more research is needed.
Jun 1, 2026
Antibiotic cement achieves 85.2% healing rate in diabetic foot osteomyelitis meta-analysis
Diabetes & Endocrinology Meta-analysis
Antibiotic cement achieves 85.2% healing rate in diabetic foot osteomyelitis meta-analysis Antibiotic cement may help heal diabetic foot infections without major surgery
A systematic review and meta-analysis of 82 patients with diabetic foot osteomyelitis found a weighted healing rate of 85.2% with antibiotic…
A meta-analysis suggests antibiotic-impregnated cement can heal diabetic foot osteomyelitis in most patients, though some still need surgery…
Jun 1, 2026